Background: Parkinson's disease (PD) is a genetically heterogeneous condition; both single nucleotide variants (SNVs) and copy number variants (CNVs) are important genetic risk factors.
Introduction
Parkinson's disease (PD) is the second most common adult-onset neurodegenerative disorder with substantial evidence for heritability. [1] [2] [3] Up to 20% of patients with PD report a positive family history [4] [5] [6] and genetic risk factors are more common in these families. 7 More than 40 different loci that increase PD susceptibility have been identified in familial and sporadic PD [8] [9] [10] [11] [12] .
Although PD is diagnosed based on clinical criteria, 13 identification of specific genetic risk factors can reveal prognostic information, such as risk of cognitive impairment and/or rate of progression, 14, 15 and may soon highlight eligibility for personalized therapies. 16, 17 In addition, discovery of risk variants may inform genetic counseling of unaffected family members. Indeed, surveys of patients and caregivers reveal a high level of interest in genetic testing for PD. 18, 19 Exome sequencing (ES) has accelerated the discovery of PD genetic risk factors [20] [21] [22] and is ideally suited to identify single nucleotide variants (SNVs) in genetically heterogeneous diseases. In one study of adult patients referred for diverse clinical indications, ES had a diagnostic yield of 10% in individuals over 30 years of age. 23 In a recent study of 80 early-onset sporadic PD cases, ES yielded an overall diagnostic rate of 11%, with GBA alleles accounting for 5%. 24 Nevertheless, clinical genetic testing is not routinely performed for PD, and ES remains poorly studied as a potential genetic diagnostic tool.
Although most identified PD risk alleles are SNVs, chromosomal structural rearrangements, or copy number variants (CNVs), also play an important role. 25 Despite notable recent advances, 26 ES remains insensitive for detection of small CNVs (< 50Kb). 27 Several complementary approaches, including multiplex ligation-dependent probe amplification. 28 bacterial artificial chromosome arrays, 29 and single nucleotide polymorphism arrays 30, 31 have shown mixed success for identification of CNVs in PD cohorts. In contrast, genome-wide array-based comparative genomic hybridization (aCGH), is a highly-validated, sensitive clinical screening tool for CNV detection, offering exon-by-exon coverage for a multitude of diseaseassociated genes. [32] [33] [34] [35] 34, 35 While not yet adopted in most diagnostic laboratories, droplet digital Polymerase Chain Reaction (ddPCR) is also emerging as a rapid and cost-efficient, targeted approach for the assessment of small CNVs at specific loci. 36 Compared to standard quantitative PCR, digital PCR offers enhanced copy number and gene dosage sensitivity, precision, and reliability due to sample partitioning. 37 We explored the genetic molecular diagnostic rate for integrated ES and aCGH in a familial PD cohort. In addition, we evaluate ddPCR for confirmation of pathogenic CNVs, and using breakpoint sequencing, we elucidate potential mechanisms for CNV formation.
Methods

Subjects
We studied 110 PD cases evaluated in the Baylor College of Medicine (BCM) PD Center and Movement Disorders Clinic in Houston, TX with a family history of PD (45% of cases reported an affected first degree relative; 55% reported a second or third degree relative). All diagnoses were made by movement disorder specialists. Subjects in our cohort were unrelated, except for 2 brothers (subjects 21 and 22) known to have PARK2-related PD. 12 However, neither ES nor aCGH were previously performed in this sibling pair. Parental and other family member samples were not available for any subjects. All subjects provided informed consent and the study was approved by the BCM Institutional Review Board. As a positive control for aCGH, we also included a sample from a known subject with an SNCA triplication. [38] [39] [40] [41] We also interrogated a Baylor Genetics diagnostic laboratory sample including 12,922 clinical referral samples for aCGH from peripheral blood. 42 This analysis of aggregate clinical genomic data was also approved by the BCM Institutional Review Board. Subject numbers throughout the text are consistent with clinical and demographic details provided in Supplementary Table 1 .
Gene Set Definition and Variant Criteria
We focused our analyses on genes and variants established to cause familial PD, including the autosomal dominant loci, SNCA (MIM#168601), 43 GBA (MIM#168600), 44 All pathogenic alleles included in this study are well-established, non-synonymous coding variants with moderate to high penetrance (OR>2) meeting stringent evidence for replication across studies or within the same study. All other variants discovered in these genes but not previously reported in PD were considered variants of unknown significance (VUSs).
SNV and CNV Detection
Genomic DNA was extracted from peripheral blood samples obtained from each participant. ES for the first 50 subjects was obtained from a prior study 21 , and ES for the remaining 60 subjects was performed at the BCM Human Genome Sequencing Center (HGSC) using the Illumina HiSeq 2000. 60 Samples achieved an average of 95% of targeted exome bases covered to a depth of 20X or greater. All pathogenic SNVs detected via ES were confirmed via Sanger sequencing.
Genome-wide array CGH was performed on 99 out of 110 subjects for which sufficient DNA remained after ES, using Baylor Genetics V10 2x400K high-density clinical-grade oligonucleotide microarrays, which were previously used for clinical diagnostic purposes. We defined potential CNVs as those regions with three or more consecutive probes with consistent direction of effect. To confirm these potential CNVs, we employed a custom 8x60K high-density array through Agilent (CA, USA). For the Baylor Genetics clinical cohort lookup, data was available from 12,922 subjects profiled for CNVs using Baylor arrays (v9 or v10). 42 CNVs were filtered according to the following criteria: 3+ consecutive probes with consistent direction of effect, log 2 ratios for loss <=0.5, gain>0.35. Filtered CNVs were manually assessed to exclude artifacts. 61 For comparison of CNV frequencies, the 2-tailed chi square test was employed. See also Supplemental Methods for further details, including ddPCR protocol.
Results
We pursued genetic diagnostic evaluation of 110 total subjects (including 109 unrelated probands) with familial PD. The mean age at onset was 50 years (SD 15); 51% were male. The ethnic composition of the cohort was 72% Caucasian, 17% Hispanic, 6% East Asian, South Asian or Middle Eastern, and 6% undefined (not reported).
Single Nucleotide Variants
We first examined subject ES data for pathogenic SNVs in established PD genes (see Methods). Figure 1A ; Supplementary Table 1 ). There was no history of cognitive impairment or dementia.
Subject 13 presented with resting tremor, rigidity and bradykinesia. She reported a family history of PD in her paternal uncle (Supplementary Figure 1B , Supplementary Table 1 ). Ten years after PD diagnosis, she developed visual hallucinations and delusions. The subjects were of European and Hispanic ancestry, respectively; neither reported Ashkenazi Jewish heritage. ES also revealed seven individuals with pathogenic variants in loci usually associated with autosomal recessive PD, including PARK2 (6 individuals) and DJ-1/PARK1 (1 individual). However, all subjects were heterozygous SNV carriers, and therefore isolated ES was non-diagnostic (Table   1 ). Therefore, based on ES alone, we identified a pathogenic variant accounting for PD in 13.8% (n=15 of 109 probands) of our familial PD cohort. All implicated variants were confirmed via Sanger sequencing. Besides the pathogenic variants noted above, ES also identified heterozygous variants of unknown significance (VUS) in many PD risk genes (Supplementary Table 2 
PARK2 (n=9), and PINK1 (n=1). For recessive PD genes, all subjects harbored a single heterozygous variant.
Copy Number Variants
We next interrogated aCGH data for pathogenic CNVs among PD genes. Our analyses included 99 out of 110 total subjects evaluated by ES. No CNVs were observed in VPS35, LRRK2, DNAJC13, GCH1, DJ1, or PINK1, nor did we identify any candidate deletions at the 22q11.2 locus. However, we discovered CNVs in SNCA (n=1), and GBA (n=1), and PARK2 (n=5). All reported CNVs were confirmed by custom high-density arrays and breakpoint sequencing. We first discuss CNVs in SNCA and GBA since these affect dominant PD genes and were considered diagnostic based on aCGH alone. All heterozygous CNVs in the recessive PD gene, PARK2, were considered further in combination with ES results (see next section). Overall, isolated aCGH identified a genetic risk factor for PD that was diagnostic in 2.0% of our cohort (n=2 of 99 probands). Based on aCGH, we have also detected numerous large CNVs (> 1 Mb) within our cohort that impact other genomic loci; these variants remain of uncertain clinical significance but are documented for completeness ( Supplementary Table 3 ).
In Subject 3, we detected a 248 kb duplication encompassing SNCA, as well as the adjacent MMRN1, which has no known association with human disease. This CNV was confirmed by high-density aCGH and breakpoint analysis ( Figure 1A ). On initial exam, this subject exhibited rigidity, tremor, gait impairment, along with hyperreflexia and clonus. The subject was of Hispanic and Native American ancestry; the subject's father had PD with dementia. Besides providing independent confirmation, breakpoint sequencing can provide clues to mechanisms of CNV formation. In the case of Subject 3, we identified a 1-bp microhomology domain, which is a short sequence that is identical to another region in the genome reduced from two copies to one during the template switch accompanying replicative repair. 62, 63 Microhomology has been reported as a signature for a class of DNA replication errors that can generate CNVs (see Discussion). 64, 65 As a positive control for our aCGH analysis, we also included a known SNCA triplication sample from the index family in which SNCA locus multiplication was first discovered as a cause for PD. [38] [39] [40] [41] Breakpoint sequencing revealed that this copy number alteration is a 1.7 Mb complex genomic rearrangement ( Figure 1B ), consisting of a duplication-inverted triplication-duplication (DUP-TRP/INV-DUP). This finding confirms and extends prior investigation of this particular structural variant 66 and is also consistent with a likely replication-based mechanism for CNV formation. 67 We also discovered a heterozygous intragenic deletion in GBA in one subject (Figure 2 ), who presented at age 28 with tremor, bradykinesia and rigidity. She had an excellent response to levodopa in her early 30s, and subsequently developed dyskinesia. The subject was of European descent, and both of her maternal grandparents were also diagnosed with PD (Supplementary Figure 1C ). Since variant confirmation at the GBA locus can be complicated by an adjacent pseudogene with significant homology, 68 we confirmed the 4.7 kb deletion of exons 2-8 using long-range PCR ( Figure 2C ). Breakpoint sequencing also confirmed heterozygosity and further revealed a 5-bp microhomology domain consistent with CNV formation due to non-homologous recombination or replication errors ( Figure 2B ).
Integrated Analysis of SNVs and CNVs
As highlighted above, isolated ES and aCGH each discovered a number of subjects with heterozygous SNVs or CNVs affecting recessive genes. In order to determine if these changes might be diagnostic, we examined the results together for potential biallelic variation at the locus due to both a SNV allele and a CNV allele. Indeed, three subjects in our cohort were newly identified as potential compound heterozygous carriers of both a pathogenic CNV and SNV in PARK2 (Figure 3 Figure 3B ). Our cohort also included 2 brothers with known PARK2 PD; 12 however, neither ES nor aCGH were previously performed. Our analysis confirmed compound heterozygosity for the known pathogenic SNV in exon 6 (c.719C>T:p.T240M, apparently homozygous on ES) and a CNV (178-kb deletion of exons 5-6) ( Figure 3C ). Interestingly, ES also discovered an additional VUS (c.2T>C:p.M1T). Table 1 ), all subjects with PARK2 variants had young-onset PD (age range .
Based on available clinical information (Supplementary
All CNVs were again confirmed using custom, high-density arrays as well as breakpoint sequencing. In the case of subject 6, we were unable to successfully amplify breakpoint junctions despite multiple attempts, suggesting a more complex genomic rearrangement or raising the possibility that this duplication is located elsewhere in the genome. For all other PARK2 CNVs, junction structure is detailed in Figure 3 , including implicated mechanisms of CNV formation.
Overall, integrated ES and CNV identified a genetic cause for PD in 4 additional probands, increasing the overall genetic diagnostic yield to 19.3% (n=21).
Digital Droplet PCR (ddPCR)
Given the observed high frequency of PARK2 CNVs in this familial PD cohort (~5%), and the high cost of clinical-grade aCGH, we examined the feasibility of exon-by-exon ddPCR assay to detect PARK2 CNVs as a proof of principle. ddPCR is an emerging cost-effective method for sensitive, and reliable assessment of specific CNVs 36, 37 . Indeed, all PARK2 CNVs described (subjects 6, 11, 20, 21 and 22) were robustly detected using ddPCR ( Figure 4A ). An additional 94 cases from our cohort with available DNA were interrogated for intragenic PARK2 CNVs, and no additional CNVs were detected ( Figure 4A and Supplementary Figure 2 ). We also applied ddPCR to screen for potential CNVs at the GBA locus. The 12-exon GBA shares high homology with a nearby 13-exon pseudogene, GBAP1. As shown in Figure 4C , using ddPCR, we successfully amplified all 12 exons of GBA. Six exons (1, 2, 4, 7, 9, and 10) identified unique amplicons with a positive droplet ratio of 1, while the other six exons (3, 5, 6, 8, 11, and 12) demonstrated shared amplicons with the pseudogene, resulting in a droplet ratio of 2.
Importantly, the deletion of GBA exons 2-8 in Subject 1 was successfully detected and confirmed by ddPCR ( Figure 4C ), and the assay was negative for GBA CNVs in 86 other samples tested ( Figures 4C and Supplementary Figure 3 ). Of note, a single exon deletion (exon 6) was suggested by ddPCR in subject 48. Further investigation revealed an intronic SNV located at the 3' end of one ddPCR primer affecting amplification efficacy, confirmed by Sanger sequencing (Supplementary Figure 4A) . We re-designed the affected primer (Supplementary Methods) and demonstrated full amplification of exon 6 (Supplementary Figure 4B) . Overall, our results suggest that ddPCR may be a sensitive and specific diagnostic tool for CNV detection in PD subjects, including at loci such as GBA complicated by genomic regions with high sequence homology.
CNV Burden in Clinical Cohorts
Compared to SNVs, limited reference data is available on the population frequency of CNVs, especially in neurologically healthy adult samples, hampering the interpretation of CNV frequencies detected in our cohort. We therefore leveraged data from the Baylor Genetics diagnostic laboratory, including 12,922 aCGH clinical referral samples. This large cohort is skewed for pediatric cases (mean age=7.4 years, SD = 9.7 years, range 0 -79 years), reflecting the more common use of aCGH in this population. Although the cohort includes a substantial proportion of individuals with developmental delay, autism and dysmorphic features, there were no recorded submissions for PD. Based on stringent criteria (see Methods), at most PD loci, CNVs were either absent (DNAJC13, LRRK2, PINK1, and SNCA) or very rare at VPS35 (n=2), GCH1 (n=1), and DJ-1 (n=6, all subjects had 1p36 deletion syndrome). By contrast, CNVs were more common at 22q11.2 (n=90, all losses affecting the critical region) and PARK2 (n=95).
Notably, the frequency of PARK2 CNVs in our PD cohort (5.1%) represents a significant enrichment (p=8.5x10 -7 ) , when compared to that of the Baylor Genetics clinical reference sample (0.74%). Due to the pseudogene, GBAP1, and suboptimal probe coverage, the array does not reliably capture GBA CNVs.
Discussion
Establishing a specific genetic diagnosis can provide information about PD risk and progression relevant to patients and their families, and may soon influence treatment decisions. 17, 69 We have evaluated combined ES and aCGH for genetic diagnosis in 110 subjects with familial PD (both assays were available for 99 subjects). In our cohort, ES and aCGH independently identified a genetic cause for PD in 13.8% and 2.0%, respectively. Our diagnostic yield for ES was slightly higher than that recently reported for an early-onset PD cohort (11.25%), 24 and was also greater than the 10.7% diagnostic rate in an unselected adult series referred for clinical diagnostic ES. 23 Given incipient treatment trials for GBA-PD and the potential importance of identifying eligible subjects in the future 69 , we included lower-risk pathogenic alleles (OR~2.4) 70 , p.E365K and p.T408M, along with higher-penetrance variants (e.g. p.L483P, OR>5) 44 . Importantly, integrated ES and aCGH identified 5 additional subjects (4 unrelated probands)-including a subject with a GBA deletion-yielding an overall combined diagnostic rate of 19.3%. Our analyses also uncovered numerous VUS, including SNVs within Mendelian PD genes (Supplementary Table   2 ) as well as large CNVs affecting other loci ( Supplementary Table 4 ). While additional evidence will be required to confirm or refute pathogenicity, our genetic diagnostic rate would nearly double if the variants in PD genes are considered bona fide risk factors. Overall, our findings suggest that complementary assessments for SNV and CNVs will be essential for routine, high-confidence genetic diagnosis in familial PD.
Most genetic diagnostic studies in PD cohorts to date have ignored the potential contribution of CNVs. Similarly, except in several notable targeted CNV studies, 29, 30, 56, 71 research-based PD gene discovery has almost exclusively focused on SNVs, using ES or genotyping arrays. 22, 72 In our familial PD cohort, pathogenic alleles at both autosomal dominant (SNCA, GBA) and recessive (PARK2) loci would have been missed if not for the inclusion of aCGH for detection of CNVs. For example, out of 7 pathogenic alleles discovered using ES at recessive loci (PARK2 and DJ-1), nearly all cases (except subjects 21 and 22) would have been non-diagnostic leading to misclassification as heterozygous carriers without aCGH. However, integrated SNV-CNV analyses successfully resolved 5 individuals with likely PARK2 PD. Our findings suggest caution for interpretation of studies attributing PD risk to either PARK2 CNV or SNV heterozygous carrier states in isolation, consistent with prior studies. 73, 74 The importance of integrated SNV-CNV analysis likely extends to other autosomal recessive PD loci, including DJ-1 and PINK1. 55, 75 Since our CNV and SNV data are unphased, and parental genotypes are not available, we cannot definitively exclude the possibility that certain CNVs and SNVs at PARK2 were in cis-rather than trans-configuration. Nevertheless, our data suggest that structural variants may co-occur with SNVs more commonly than previously recognized, making consideration of both allele types important for comprehensive genetic diagnosis in PD. 76 ES has significantly accelerated the scope of gene discovery in PD and other neurologic disorders, 22, 24 but remains insensitive to allele classes such as trinucleotide repeat expansions and CNVs. While bioinformatic tools can be employed to screen for CNVs in data from ES, available algorithms have high false positive rates compared to aCGH 77 and as many as 30% of clinically relevant CNVs are missed by ES. 27 To our knowledge, genome-wide aCGH with exonby-exon coverage has not been previously applied in PD. Limitations of aCGH include significant cost, and the possibility of missing small deletions/duplications. Alternative methods, such as ddPCR, may offer a cost effective alternative for screening specific genes, 36 including for small CNVs. In our study, ddPCR showed high sensitivity and specificity for detection of CNVs at both PARK2 and GBA. In the latter case, ddPCR was able to robustly differentiate copy number changes affecting exons unique to GBA avoiding potential confounding by the adjacent pseudogene, GBAP1.
Despite evidence of an important role in disease risk, the mechanism(s) responsible for generating CNVs relevant to PD have been poorly studied. Broadly, CNVs may form through mechanisms associated with DNA recombination, DNA replication, and/or DNA repair. 62 Mechanisms such as nonallelic homologous recombination [78] [79] [80] can result in recurrent rearrangements. In contrast, non-homologous end joining, 64, 81 fork stalling and template switching (FoSTeS) and microhomology-mediated break-induced replication (MMBIR), 64 lead to non-recurrent CNVs. In our study, for all CNVs for which breakpoint junctions were obtained, the mechanism was consistent with FoSTeS/MMBIR. This finding has important implications for screening assays since methods sensitive for heterogeneous, exon-by-exon changes must be employed to detect non-recurrent CNVs. The FoSTeS/MMBIR mechanism can also trigger multiple iterative template switches in a single event, leading to the generation of more complex genomic rearrangements. Breakpoint sequencing of an SNCA CNV first observed in the Spellman-Muenter/Iowa kindred, 40, 82 confirmed the DUP-TRP-DUP structure 66 and further revealed an internal inversion (DUP-TRP/INV-DUP) and also revealed microhomology. This rearrangement must have arisen during mitosis via FoSTeS/MMBIR 62, 64, 83, 84 and therefore likely represents a de novo triplication, in contrast to the meiotic PMP22 triplications observed in Charcot Marie Tooth (MIM#118220), which derives from a duplication in the previous generation. 85 Our results therefore demonstrate the essential role of breakpoint junction sequencing in definitively resolving CNV structure and responsible mechanisms.
To our knowledge, our study includes the first report of an intragenic GBA deletion allele in a subject with PD. Similar deletions in GBA have been rarely described in autosomal recessive Gaucher disease (MIM#230800). [86] [87] [88] Our discovery of a GBA deletion allele, expected to cause glucocerobrosidase haploinsufficiency, adds to other emerging evidence supporting a loss-offunction mechanism in GBA-associated PD. 89, 90 It will be informative to screen for additional GBA CNVs in additional case/control cohorts-perhaps using ddPCR-to determine how commonly these alleles are associated with PD risk and estimate their effect size and penetrance.
We also identified 2 subjects in our cohort doubly heterozygous for SNVs in both GBA and LRRK2, and similar PD cases have been previously reported. 91 As comprehensive, genome-wide diagnostic approaches, including ES and aCGH, become widely utilized in PD, it is likely that additional cases compatible with oligogenic inheritance models will be recognized. 92, 93 Future studies will be required to define whether and how such alleles may interact to modify PD risk and/or clinical manifestations. Finally, while our study focused on pathogenic alleles in established, Mendelian loci, future assessment of a more complete spectrum of genetic variation through integrated SNV-CNV analysis is also likely to enhance power for novel PD gene discovery. 
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